Chris Murphy actually said...

These reductions will result in significant savings to the healthcare system and patients as the biosimilar market matures.

Thank you, Mr. Chairman.

Biologics have provided major advances in the treatment of cancer, rheumatologic disease, and other conditions.

It took us a long time to educate both providers and patients about chemical generics.